Solve Therapeutics, Inc.

Solve Therapeutics, Inc. is a US-based biotechnology firm focused on developing innovative therapies through advanced antibody-drug conjugates to address complex medical conditions. Founded in 2021 and headquartered in Alameda, US, Solve Therapeutics, Inc. specializes in biopharmaceutical development.

The company has raised USD 120. 00 mn in its latest funding round on November 17, 2025, led by Yosemite Management with participation from several prominent investors. The total amount raised since inception is USD 120. 00 mn.

The founder's previous ventures and details about additional subsidiaries or parent companies are not disclosed. Solve Therapeutics, Inc. focuses on developing advanced antibody-drug conjugates aimed at improving treatment efficacy for various diseases. Their innovative portfolio targets complex health challenges, contributing to the advancement of therapeutic options in the biopharmaceutical industry.

The revenue model of Solve Therapeutics, Inc. relies on strategic partnerships with various enterprises, centered around the commercialization of their proprietary therapies. Clients engage with the company through structured agreements that ensure ongoing support and access to their advanced drug development programs, establishing a reliable revenue stream. With the recent funding of USD 120.

00 mn secured in November 2025, Solve Therapeutics, Inc. plans to advance its antibody-drug conjugate pipeline and complete Phase 1b studies for its lead programs. The company is also exploring opportunities for expansion into new therapeutic areas by targeting additional markets and regions, with specific timelines yet to be disclosed.